Sorbents in Acute Renal Failure and End-Stage Renal Disease: Middle Molecule and Cytokine Removal
Renal replacement therapy in acute renal failure (ARF) and chronic renal failure (end-stage renal disease; ESRD) has been based on the use of modifications of dialysis (continuous arteriovenous hemofiltration and hemodiafiltration) to remove middle-molecular-weight toxins, consisting of low-molecula...
Gespeichert in:
| Veröffentlicht in: | Blood purification 2004-01, Vol.22 (1), p.73-77 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 77 |
|---|---|
| container_issue | 1 |
| container_start_page | 73 |
| container_title | Blood purification |
| container_volume | 22 |
| creator | Winchester, James F. Silberzweig, Jeffrey Ronco, Claudio Kuntsevich, Viktoria Levine, Daniel Parker, Tom Kellum, John A. Salsberg, Jamie A. Quartararo, Peter Levin, Nathan W. |
| description | Renal replacement therapy in acute renal failure (ARF) and chronic renal failure (end-stage renal disease; ESRD) has been based on the use of modifications of dialysis (continuous arteriovenous hemofiltration and hemodiafiltration) to remove middle-molecular-weight toxins, consisting of low-molecular-weight proteins and peptides (LMWP) and cytokines involved in inflammation. High-flux dialyzers are not efficient at removing LMWP, and for this reason, sorbents have been studied to augment or replace dialysis. Removal of LMWP such as β 2 -microglobulin, leptin, complement factor D, angiogenin and cytokines such as interleukin (IL)-1, IL-6, IL-10, IL-18 and tumor necrosis factor-α has been established in animal models of sepsis and in ESRD patients using sorbents. Sorbent devices added to hemodialysis, or the use of such devices alone in inflammatory states, including sepsis, ARF, cardiopulmonary bypass, pre-explantation of donor organs and ESRD, are being studied. |
| doi_str_mv | 10.1159/000074926 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_80101608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>80101608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-e3e6d659677fcf573fb21ffb4c7b21028a42adf1e09a2cd3e9b406e49eff9d053</originalsourceid><addsrcrecordid>eNpt0MtrFEEQB-D2hdnEHDwLMgQUPIz2--EtrokKCYox56GmuzqM6Z1Zu2eE_PeZdTfJxb5UQ31UFT9CXjL6njHlPtD5Gem4fkQOnbFCMEsZlc48JgsmOaudEeoJ2ReWKmW0FfYpWVCuRK2otntkv5TflDKplXtO9pg0glsmFwQuhtxiP5aq66tjP41Y_cQeUnUKXZoyVtCH6qQP9cUIV3e9z11BKPixOu9CSFidDwn9lLZ4eTMO112_savhL6QX5FmEVPBwVw_I5enJr-XX-uz7l2_L47PaSy7HGgXqMF-njYk-KiNiy1mMrfRm_lBuQXIIkSF1wH0Q6FpJNUqHMbpAlTggb7dz13n4M2EZm1VXPKYEPQ5TaTZ5MU3tDN9toc9DKRljs87dCvJNw2izCbu5D3u2r3dDp3aF4UHuApzBmx2A4iHFDL3vyoNTUnPqxOxebd015CvM9-BuzdF_u59-XP4DzTpEcQurb5WX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>80101608</pqid></control><display><type>article</type><title>Sorbents in Acute Renal Failure and End-Stage Renal Disease: Middle Molecule and Cytokine Removal</title><source>MEDLINE</source><source>Karger Journals</source><creator>Winchester, James F. ; Silberzweig, Jeffrey ; Ronco, Claudio ; Kuntsevich, Viktoria ; Levine, Daniel ; Parker, Tom ; Kellum, John A. ; Salsberg, Jamie A. ; Quartararo, Peter ; Levin, Nathan W.</creator><creatorcontrib>Winchester, James F. ; Silberzweig, Jeffrey ; Ronco, Claudio ; Kuntsevich, Viktoria ; Levine, Daniel ; Parker, Tom ; Kellum, John A. ; Salsberg, Jamie A. ; Quartararo, Peter ; Levin, Nathan W.</creatorcontrib><description>Renal replacement therapy in acute renal failure (ARF) and chronic renal failure (end-stage renal disease; ESRD) has been based on the use of modifications of dialysis (continuous arteriovenous hemofiltration and hemodiafiltration) to remove middle-molecular-weight toxins, consisting of low-molecular-weight proteins and peptides (LMWP) and cytokines involved in inflammation. High-flux dialyzers are not efficient at removing LMWP, and for this reason, sorbents have been studied to augment or replace dialysis. Removal of LMWP such as β 2 -microglobulin, leptin, complement factor D, angiogenin and cytokines such as interleukin (IL)-1, IL-6, IL-10, IL-18 and tumor necrosis factor-α has been established in animal models of sepsis and in ESRD patients using sorbents. Sorbent devices added to hemodialysis, or the use of such devices alone in inflammatory states, including sepsis, ARF, cardiopulmonary bypass, pre-explantation of donor organs and ESRD, are being studied.</description><identifier>ISSN: 0253-5068</identifier><identifier>ISBN: 3805576838</identifier><identifier>ISBN: 9783805576833</identifier><identifier>EISSN: 1421-9735</identifier><identifier>EISBN: 9783318010497</identifier><identifier>EISBN: 3318010499</identifier><identifier>DOI: 10.1159/000074926</identifier><identifier>PMID: 14732814</identifier><identifier>CODEN: BLPUDO</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Acute Kidney Injury - blood ; Acute Kidney Injury - therapy ; Adsorption ; Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Animals ; Biological and medical sciences ; Blood Proteins - metabolism ; Clinical Trials as Topic ; Cytokines - blood ; Emergency and intensive care: renal failure. Dialysis management ; Female ; Hemoperfusion - methods ; Humans ; Inflammation - blood ; Intensive care medicine ; Kidney Failure, Chronic - blood ; Kidney Failure, Chronic - therapy ; Male ; Medical sciences ; Middle Aged ; Molecular Weight ; Nephrology. Urinary tract diseases ; Nephropathies. Renovascular diseases. Renal failure ; Peptides - blood ; Renal failure ; Resins, Synthetic - chemistry ; Sepsis - blood ; Sepsis - therapy ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Treatment Outcome</subject><ispartof>Blood purification, 2004-01, Vol.22 (1), p.73-77</ispartof><rights>2004 S. Karger AG, Basel</rights><rights>2004 INIST-CNRS</rights><rights>Copyright 2004 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-e3e6d659677fcf573fb21ffb4c7b21028a42adf1e09a2cd3e9b406e49eff9d053</citedby><cites>FETCH-LOGICAL-c424t-e3e6d659677fcf573fb21ffb4c7b21028a42adf1e09a2cd3e9b406e49eff9d053</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,2429,4024,4050,4051,23930,23931,25140,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15462093$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14732814$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Winchester, James F.</creatorcontrib><creatorcontrib>Silberzweig, Jeffrey</creatorcontrib><creatorcontrib>Ronco, Claudio</creatorcontrib><creatorcontrib>Kuntsevich, Viktoria</creatorcontrib><creatorcontrib>Levine, Daniel</creatorcontrib><creatorcontrib>Parker, Tom</creatorcontrib><creatorcontrib>Kellum, John A.</creatorcontrib><creatorcontrib>Salsberg, Jamie A.</creatorcontrib><creatorcontrib>Quartararo, Peter</creatorcontrib><creatorcontrib>Levin, Nathan W.</creatorcontrib><title>Sorbents in Acute Renal Failure and End-Stage Renal Disease: Middle Molecule and Cytokine Removal</title><title>Blood purification</title><addtitle>Blood Purif</addtitle><description>Renal replacement therapy in acute renal failure (ARF) and chronic renal failure (end-stage renal disease; ESRD) has been based on the use of modifications of dialysis (continuous arteriovenous hemofiltration and hemodiafiltration) to remove middle-molecular-weight toxins, consisting of low-molecular-weight proteins and peptides (LMWP) and cytokines involved in inflammation. High-flux dialyzers are not efficient at removing LMWP, and for this reason, sorbents have been studied to augment or replace dialysis. Removal of LMWP such as β 2 -microglobulin, leptin, complement factor D, angiogenin and cytokines such as interleukin (IL)-1, IL-6, IL-10, IL-18 and tumor necrosis factor-α has been established in animal models of sepsis and in ESRD patients using sorbents. Sorbent devices added to hemodialysis, or the use of such devices alone in inflammatory states, including sepsis, ARF, cardiopulmonary bypass, pre-explantation of donor organs and ESRD, are being studied.</description><subject>Acute Kidney Injury - blood</subject><subject>Acute Kidney Injury - therapy</subject><subject>Adsorption</subject><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood Proteins - metabolism</subject><subject>Clinical Trials as Topic</subject><subject>Cytokines - blood</subject><subject>Emergency and intensive care: renal failure. Dialysis management</subject><subject>Female</subject><subject>Hemoperfusion - methods</subject><subject>Humans</subject><subject>Inflammation - blood</subject><subject>Intensive care medicine</subject><subject>Kidney Failure, Chronic - blood</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Weight</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Nephropathies. Renovascular diseases. Renal failure</subject><subject>Peptides - blood</subject><subject>Renal failure</subject><subject>Resins, Synthetic - chemistry</subject><subject>Sepsis - blood</subject><subject>Sepsis - therapy</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Treatment Outcome</subject><issn>0253-5068</issn><issn>1421-9735</issn><isbn>3805576838</isbn><isbn>9783805576833</isbn><isbn>9783318010497</isbn><isbn>3318010499</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpt0MtrFEEQB-D2hdnEHDwLMgQUPIz2--EtrokKCYox56GmuzqM6Z1Zu2eE_PeZdTfJxb5UQ31UFT9CXjL6njHlPtD5Gem4fkQOnbFCMEsZlc48JgsmOaudEeoJ2ReWKmW0FfYpWVCuRK2otntkv5TflDKplXtO9pg0glsmFwQuhtxiP5aq66tjP41Y_cQeUnUKXZoyVtCH6qQP9cUIV3e9z11BKPixOu9CSFidDwn9lLZ4eTMO112_savhL6QX5FmEVPBwVw_I5enJr-XX-uz7l2_L47PaSy7HGgXqMF-njYk-KiNiy1mMrfRm_lBuQXIIkSF1wH0Q6FpJNUqHMbpAlTggb7dz13n4M2EZm1VXPKYEPQ5TaTZ5MU3tDN9toc9DKRljs87dCvJNw2izCbu5D3u2r3dDp3aF4UHuApzBmx2A4iHFDL3vyoNTUnPqxOxebd015CvM9-BuzdF_u59-XP4DzTpEcQurb5WX</recordid><startdate>200401</startdate><enddate>200401</enddate><creator>Winchester, James F.</creator><creator>Silberzweig, Jeffrey</creator><creator>Ronco, Claudio</creator><creator>Kuntsevich, Viktoria</creator><creator>Levine, Daniel</creator><creator>Parker, Tom</creator><creator>Kellum, John A.</creator><creator>Salsberg, Jamie A.</creator><creator>Quartararo, Peter</creator><creator>Levin, Nathan W.</creator><general>Karger</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200401</creationdate><title>Sorbents in Acute Renal Failure and End-Stage Renal Disease: Middle Molecule and Cytokine Removal</title><author>Winchester, James F. ; Silberzweig, Jeffrey ; Ronco, Claudio ; Kuntsevich, Viktoria ; Levine, Daniel ; Parker, Tom ; Kellum, John A. ; Salsberg, Jamie A. ; Quartararo, Peter ; Levin, Nathan W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-e3e6d659677fcf573fb21ffb4c7b21028a42adf1e09a2cd3e9b406e49eff9d053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Acute Kidney Injury - blood</topic><topic>Acute Kidney Injury - therapy</topic><topic>Adsorption</topic><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood Proteins - metabolism</topic><topic>Clinical Trials as Topic</topic><topic>Cytokines - blood</topic><topic>Emergency and intensive care: renal failure. Dialysis management</topic><topic>Female</topic><topic>Hemoperfusion - methods</topic><topic>Humans</topic><topic>Inflammation - blood</topic><topic>Intensive care medicine</topic><topic>Kidney Failure, Chronic - blood</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Weight</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Nephropathies. Renovascular diseases. Renal failure</topic><topic>Peptides - blood</topic><topic>Renal failure</topic><topic>Resins, Synthetic - chemistry</topic><topic>Sepsis - blood</topic><topic>Sepsis - therapy</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Winchester, James F.</creatorcontrib><creatorcontrib>Silberzweig, Jeffrey</creatorcontrib><creatorcontrib>Ronco, Claudio</creatorcontrib><creatorcontrib>Kuntsevich, Viktoria</creatorcontrib><creatorcontrib>Levine, Daniel</creatorcontrib><creatorcontrib>Parker, Tom</creatorcontrib><creatorcontrib>Kellum, John A.</creatorcontrib><creatorcontrib>Salsberg, Jamie A.</creatorcontrib><creatorcontrib>Quartararo, Peter</creatorcontrib><creatorcontrib>Levin, Nathan W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Blood purification</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Winchester, James F.</au><au>Silberzweig, Jeffrey</au><au>Ronco, Claudio</au><au>Kuntsevich, Viktoria</au><au>Levine, Daniel</au><au>Parker, Tom</au><au>Kellum, John A.</au><au>Salsberg, Jamie A.</au><au>Quartararo, Peter</au><au>Levin, Nathan W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sorbents in Acute Renal Failure and End-Stage Renal Disease: Middle Molecule and Cytokine Removal</atitle><jtitle>Blood purification</jtitle><addtitle>Blood Purif</addtitle><date>2004-01</date><risdate>2004</risdate><volume>22</volume><issue>1</issue><spage>73</spage><epage>77</epage><pages>73-77</pages><issn>0253-5068</issn><eissn>1421-9735</eissn><isbn>3805576838</isbn><isbn>9783805576833</isbn><eisbn>9783318010497</eisbn><eisbn>3318010499</eisbn><coden>BLPUDO</coden><abstract>Renal replacement therapy in acute renal failure (ARF) and chronic renal failure (end-stage renal disease; ESRD) has been based on the use of modifications of dialysis (continuous arteriovenous hemofiltration and hemodiafiltration) to remove middle-molecular-weight toxins, consisting of low-molecular-weight proteins and peptides (LMWP) and cytokines involved in inflammation. High-flux dialyzers are not efficient at removing LMWP, and for this reason, sorbents have been studied to augment or replace dialysis. Removal of LMWP such as β 2 -microglobulin, leptin, complement factor D, angiogenin and cytokines such as interleukin (IL)-1, IL-6, IL-10, IL-18 and tumor necrosis factor-α has been established in animal models of sepsis and in ESRD patients using sorbents. Sorbent devices added to hemodialysis, or the use of such devices alone in inflammatory states, including sepsis, ARF, cardiopulmonary bypass, pre-explantation of donor organs and ESRD, are being studied.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>14732814</pmid><doi>10.1159/000074926</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-5068 |
| ispartof | Blood purification, 2004-01, Vol.22 (1), p.73-77 |
| issn | 0253-5068 1421-9735 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_80101608 |
| source | MEDLINE; Karger Journals |
| subjects | Acute Kidney Injury - blood Acute Kidney Injury - therapy Adsorption Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Animals Biological and medical sciences Blood Proteins - metabolism Clinical Trials as Topic Cytokines - blood Emergency and intensive care: renal failure. Dialysis management Female Hemoperfusion - methods Humans Inflammation - blood Intensive care medicine Kidney Failure, Chronic - blood Kidney Failure, Chronic - therapy Male Medical sciences Middle Aged Molecular Weight Nephrology. Urinary tract diseases Nephropathies. Renovascular diseases. Renal failure Peptides - blood Renal failure Resins, Synthetic - chemistry Sepsis - blood Sepsis - therapy Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Treatment Outcome |
| title | Sorbents in Acute Renal Failure and End-Stage Renal Disease: Middle Molecule and Cytokine Removal |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T11%3A25%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sorbents%20in%20Acute%20Renal%20Failure%20and%20End-Stage%20Renal%20Disease:%20Middle%20Molecule%20and%20Cytokine%20Removal&rft.jtitle=Blood%20purification&rft.au=Winchester,%20James%20F.&rft.date=2004-01&rft.volume=22&rft.issue=1&rft.spage=73&rft.epage=77&rft.pages=73-77&rft.issn=0253-5068&rft.eissn=1421-9735&rft.isbn=3805576838&rft.isbn_list=9783805576833&rft.coden=BLPUDO&rft_id=info:doi/10.1159/000074926&rft_dat=%3Cproquest_cross%3E80101608%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&rft.eisbn=9783318010497&rft.eisbn_list=3318010499&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=80101608&rft_id=info:pmid/14732814&rfr_iscdi=true |